Clinical Trials Browser

Terminated × Has results × infigratinib × Clear all

NCT04504331 2026-02-12

Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer

Phase 1 Terminated

4 enrolled 11 charts

Breast Neoplasms

NCT04424966 2025-10-24

Infigratinib in Recurrent High-Grade Glioma Patients

Phase EARLY_PHASE1 Terminated

7 enrolled 18 charts

Glioblastoma, Glioma

NCT04228042 2025-01-01

Infigratinib Before Surgery for the Treatment of Upper Tract Urothelial Cancer

Phase 1/2 Terminated

15 enrolled 10 charts

Renal Pelvis and Ureter Urothelial Carcinoma

NCT03773302 2024-05-08

Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations

Phase 3 Terminated

48 enrolled 26 charts

Gastrointestinal

Cholangiocarcinoma

NCT04197986 2024-03-13

PROOF302

Phase 3 Terminated

39 enrolled 31 charts

Upper Tract Urothelial Carcinomas

NCT02150967 2023-07-03

A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma

Phase 2 Terminated

143 enrolled 25 charts 2 FDA

Gastrointestinal

Cholangiocarcinoma

NCT03510455 2021-04-08

BGJ398 for the Treatment of Tumor-Induced Osteomalacia

Phase 2 Terminated

4 enrolled 28 charts

Oncogenic osteomalacia, Hypophosphatemia

NCT02160041 2019-06-18

CBGJ398XUS04

Phase 2 Terminated

84 enrolled 15 charts

Other hematologic neoplasm

Hematologic Neoplasms

NCT02706691 2019-04-16

BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer

Phase 2 Terminated

1 enrolled 8 charts

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Neoplasms, Papillomavirus Infections